The current drug discovery process is failing. Millions of people die of curable diseases every year. At Everlume we have developed a new model of drug discovery and are pioneering a direct to patient approach that not only gives patients access to genetic based cures, but in record time.
The market for rare disease treatments is severely underserved, with over 300 million people worldwide affected by these conditions and only 5% having an approved treatment. Traditional pharmaceutical companies often overlook rare diseases due to the high costs and long timelines associated with drug development, leaving patients and their families with few options and little hope. Everlume is addressing this critical gap by revolutionizing the drug discovery process, making it faster, more affordable, and directly responsive to the unique needs of rare disease patients. Our innovative approach not only accelerates the development of life-saving treatments but also empowers families by putting them at the center of the cure process. By focusing on rare diseases, we are tapping into a market that is not just large and growing, but also in desperate need of innovative solutions.
We have created two patented genetic based therapeutics. One is a gene therapy for Hereditary Spastic Paraplegia and the other is an ASO for a mutation in the HNRNPH2 gene. These should be in trial and given to our first batch of patients by the end of next year.
Doing over $1M in annual revenue
